Introduction {#s1}
============

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by age-inappropriate levels of impulsiveness, inattention, and hyperactivity ([@BHT365C2]). Autism spectrum disorder (ASD) is defined by impairments in communication, social interaction, and also by restricted and repetitive behaviors ([@BHT365C2]). ADHD and ASD are highly comorbid and both disorders share executive function deficits ([@BHT365C142]; [@BHT365C26]; [@BHT365C107]), including poor cognitive flexibility ([@BHT365C61]; [@BHT365C142]; [@BHT365C120]), which has been linked to repetitive behaviors in ASD ([@BHT365C146]). The clinical importance of this behavioral and cognitive overlap has been highlighted by changes to the upcoming DSM-V, which allows co-diagnosis of ADHD and ASD (<http://www.dsm5.org>).

Cognitive flexibility can be measured in switching and reversal tasks, where stimulus-response associations need to be either changed to new, or reversed to previous stimulus-response associations, respectively. It is known that the prefrontal cortex is involved in many aspects of cognition, and that the same region can play a role in a number of functions ([@BHT365C56]; [@BHT365C3]). However, the cognitive processes of switching and reward reversal learning involve quite different neuronal circuitry. During switching tasks, healthy children and adults activate inferior frontal cortex (IFC), dorsolateral prefrontal cortex (DLPFC), anterior cingulate cortex (ACC), and parietal lobe ([@BHT365C36]; [@BHT365C74]; [@BHT365C118]; [@BHT365C102]; [@BHT365C20]). During reward reversal learning tasks, in healthy adults, due to the emotional valence of the reward and punishment present in reward reversal learning tasks, more medial brain regions, including medial prefrontal cortex (mPFC), medial orbitofrontal cortex (OFC), and ACC, are typically recruited ([@BHT365C91], [@BHT365C90]; [@BHT365C25]; [@BHT365C103]; [@BHT365C23]; [@BHT365C69]). Striatal activation is also observed during reward reversal learning due to the role of the striatum in reward-related habitual learning and stimulus-response associations, with more ventral striatal regions involved in reversal learning ([@BHT365C25]; [@BHT365C93]; [@BHT365C103]; [@BHT365C147]) and more anterior striatal regions being implicated in switching ([@BHT365C118]; [@BHT365C20]).

fMRI studies of switch tasks have found decreased activation in ADHD children compared with controls in the IFC, temporo-parietal junction, and striatum ([@BHT365C130]; [@BHT365C110]; [@BHT365C111]). ADHD patients have been shown to have abnormal medial frontal and precuneus activation during reward reversal tasks ([@BHT365C47]). In ASD children, no fMRI study has investigated cognitive flexibility. In adult ASD, however, 2 studies have reported conflicting evidence of decreased activation in the DLPFC, ACC, and basal ganglia ([@BHT365C123]), and increased activation in the IFC and parietal lobe relative to controls ([@BHT365C121]).

5-HT and dopamine interact in the prefrontal cortex, resulting in the fine tuning of neuronal responses and better cognition, particularly in tasks that require the maintenance of stimulus-response representations ([@BHT365C55]). There is evidence that 5-HT is involved in reward reversal learning ([@BHT365C85]; [@BHT365C44]; [@BHT365C105]). Furthermore, there is evidence that 5-HT is involved in the pathology of both ADHD and ASD.

Thus, polymorphisms of serotonergic genes have been associated with both ADHD and ASD ([@BHT365C127]; [@BHT365C106]), and there is evidence that a polymorphism of the 5-HT transporter gene may play a role in the ADHD symptoms observed in ASD ([@BHT365C49]). Moreover, biochemical serotonergic dysfunction has been implicated in both ADHD ([@BHT365C88]) and ASD ([@BHT365C148]). In children with ADHD, there is evidence for decreased platelet 5-HT levels ([@BHT365C132]) and increased ADHD behavior after a reduction in 5-HT ([@BHT365C150], [@BHT365C149]). Conversely, one-third of the individuals with ASD have abnormally elevated 5-HT platelet levels ([@BHT365C97]; [@BHT365C82]; [@BHT365C65]). In addition, in ASD, abnormal 5-HT synthesis ([@BHT365C22], [@BHT365C21]), 5-HT transporter ([@BHT365C77]; [@BHT365C86]), and 5-HT~2A~ receptor binding ([@BHT365C84]) have also been reported. Clinical trials of Fluoxetine in children with ASD have shown improvement in communication, social interaction, and stereotyped behaviors ([@BHT365C34], [@BHT365C33]; [@BHT365C63]; [@BHT365C15]), although effects are small ([@BHT365C143]). In addition, SSRIs have shown to increase metabolic and neurofunctional activity in adults with ASD in areas mediating reward reversal learning such as OFC/mPFC, ACC, and striatum ([@BHT365C81]; [@BHT365C48]), which was associated with reduced obsessive behavior ([@BHT365C11]; [@BHT365C37]).

In ADHD children, Fluoxetine monotherapy has been shown to significantly improve inattentiveness and hyperactivity in noncomorbid groups ([@BHT365C5]), as well as in groups with co-morbid bipolar disorder ([@BHT365C99]). Fluoxetine also appears to moderate the efficacy of stimulant medication, as evidenced by the finding that combined Fluoxetine--Methylphenidate treatment reduces ADHD symptoms in co-morbid ADHD children ([@BHT365C51]; [@BHT365C46]). There is evidence that 5-HT and dopamine interact, in particular, with respect to impulsiveness ([@BHT365C30]) and the serotonergic system has been shown to play a key regulatory role in dopamine release ([@BHT365C124]; [@BHT365C39]), which is typically low in ADHD ([@BHT365C140]; [@BHT365C32]). The importance of 5-HT-dopamine interactions in ADHD is further reinforced by evidence for abnormal ratios and correlations between 5-HT and dopamine levels in children with ADHD ([@BHT365C16]; [@BHT365C89]). There is also evidence that response to stimulants is mediated by 5-HT in animal ([@BHT365C50]) and human studies as an association between serotonergic genes and Methylphenidate response has been observed ([@BHT365C79]; [@BHT365C4]). In addition, the co-administration of 5-HT and dopamine amino acids precursors in children with ADHD has been shown to lead to a significant improvement in symptoms ([@BHT365C62]). Therefore, when used in combination, Fluoxetine may lead to better regulation of the increased dopamine induced by Methylphenidate, leading to clinical improvement ([@BHT365C5]; [@BHT365C51]; [@BHT365C46]; [@BHT365C99]). This is in line with the seminal animal study of [@BHT365C50]) which showed that, in mice, the effect of Methylphenidate was dependent on 5-HT.

In conclusion, there is evidence for impaired cognitive flexibility and underlying neurofunctional brain mechanisms in ADHD ([@BHT365C142]; [@BHT365C130]; [@BHT365C47]; [@BHT365C110]; [@BHT365C111]) and in ASD ([@BHT365C61]; [@BHT365C121]; [@BHT365C120]; [@BHT365C123]). Furthermore, both disorders have shown 5-HT abnormalities ([@BHT365C97]; [@BHT365C132]; [@BHT365C82]; [@BHT365C65]; [@BHT365C88]; [@BHT365C148]), which may possibly underlie these cognitive flexibility deficits. In addition, Fluoxetine has shown to improve behavior in these 2 disorders ([@BHT365C5]; [@BHT365C51]; [@BHT365C34], [@BHT365C33]; [@BHT365C63]; [@BHT365C99]; [@BHT365C15]), and to modify cognitive flexibility and underlying neural networks in healthy subjects ([@BHT365C44]; [@BHT365C105]).

The aim of this study was therefore to investigate (1) shared and disorder-specific brain abnormalities in adolescents with ADHD and those with ASD during reward reversal learning and (2) shared and disorder-specific neurofunctional effects of an acute dose of Fluoxetine on this function in both disorders.

Based on prior evidence ([@BHT365C130]; [@BHT365C47]; [@BHT365C123]; [@BHT365C110]; [@BHT365C111]), we hypothesized that, under placebo, both disorders would show abnormal switching related activation in compared with controls, with more prominent IFC-striatal deficits in ADHD, and more prominent DLPFC and mPFC abnormalities in ASD. We also hypothesized that Fluoxetine would normalize these neurofunctional abnormalities in both disorders.

Materials and Methods {#s2}
=====================

Participants {#s2a}
------------

Fifty-four right-handed males (assessed with the Edinburgh Handedness Inventory; [@BHT365C92]; 21 controls, 15 with ADHD, and 18 with ASD), aged 10--17 years, IQ \>70 (assessed with the Wechsler Abbreviated Scale of Intelligence-Revised; [@BHT365C141]), participated.

Thirty-two ADHD boys were recruited in total; however, 10 boys dropped out of the study due to their dislike of the MRI scanner, 3 were excluded due to co-morbidities (despite the fact we explicitly aimed to recruit only noncomorbid cases), 1 did not reach the diagnostic criteria for the combined subtype of ADHD, 1 was excluded due to poor task performance, and 2 were excluded due to high levels of motion.

ADHD boys had a DSM-IV diagnosis of noncomorbid ADHD, inattentive/hyperactive-impulsive combined subtype, as assessed by an experienced child psychiatrist using the standardized Maudsley diagnostic interview ([@BHT365C54]). They scored above clinical threshold for ADHD on both the Strengths and Difficulties Questionnaire (SDQ) ([@BHT365C57]) and the Conners\' Parent Rating Scale-Revised (CPRS-R; [@BHT365C24]) (1 boy was below cut-off on SDQ, but had diagnostic confirmation from a child psychiatrist). Three of the ADHD boys were medication-naïve, 1 had ceased taking Methylphenidate 3 months prior to the study, and 11 were on chronic stimulants, but had a 48-h medication washout prior to scanning. ADHD boys were excluded if they scored \>15 on the Social Communication Questionnaire (SCQ; [@BHT365C119]).

Forty-four ASD boys were recruited in total. Of these, 7 boys dropped out of the study due to their dislike of the MRI scanner, 14 were excluded due to co-morbidities, 1 was excluded due to neurological abnormalities, 2 were excluded due to SSRI use, and 2 were excluded due to high levels of motion. ASD diagnosis was made using ICD-10 diagnostic criteria ([@BHT365C145]) and confirmed by the Autism Diagnostic Interview-Revised (ADI; [@BHT365C76]) and the Autism Diagnostic Observation Schedule (ADOS; [@BHT365C75]). All ASD subjects were medication-naïve apart from 1 patient, who took melatonin (but underwent 2-week medication washout). ASD exclusion criteria included a score of \>7 on the hyperactivity/inattention subscale of the SDQ.

DSM-IV as opposed to DSM-V criteria was used to confirm both ADHD and ASD diagnoses, as DSM-V was not available for clinical use at the time of testing. As previously mentioned, DSM-V allows co-diagnosis of ADHD and ASD and therefore would have enabled easier identification and exclusion of comorbid cases. However, rigorous screening ensured that clinical levels of ADHD and ASD traits were not present in ASD or ADHD participants, respectively.

Patients were recruited from local clinics and support groups. They were scanned twice in a double-blind, randomized, placebo-controlled design, using a Latin square randomization design for counter-balanced effects. Due to the half-life of Fluoxetine (1--3 days) and its metabolite Norfluoxetine (5--16 days) ([@BHT365C144]), each scan was 3--4 weeks apart. To ensure that Fluoxetine had reached its peak plasma levels, shown to be after 5--8 h ([@BHT365C144]), patients were scanned 5 h after administration. Liquid Fluoxetine was titrated to age and weight as follows: boys between 10--13 years and \<30 kg received 8 mg, those \>30 kg received 10 mg. Boys between 14--17 years and \<30 kg received 10 mg, and those \>30 kg received 15 mg. Placebo was peppermint water, which was similar in taste to Fluoxetine and measured to the equivalent volume.

Twenty-one handedness and age-matched controls were recruited by advertisement. They all scored below clinical thresholds on the SDQ, SCQ, and CPRS. Controls were scanned only once. Drug/alcohol dependency was an exclusion criterium for all participants.

Written informed consent/assent was given for all participants. The study was approved by the local ethics committee. Participants were paid £50 for each scan.

fMRI Paradigm---Reward Reversal Learning {#s2b}
----------------------------------------

Subjects practiced the task once prior to each scan. Our fMRI adaptation is similar to the probabilistic reward reversal learning task employed by [@BHT365C25]). The semi-self-paced reward reversal learning task requires subjects to learn a stimulus-response association by reward and punishment and to reverse their response when the stimulus-reward contingency changes unexpectedly. Images of a car and a spaceship are displayed simultaneously on the left and right side (randomized) of a black screen for 1950 ms. The subject has to choose with a left or right button press the correct choice, indicated by feedback via an image of a 50 pence piece and a green happy smiley, whereas the incorrect choice is indicated by an image of a crossed-out 50 pence piece and a red unhappy smiley, both displayed after the choice for 950 ms. There is a 100-ms gap between each trial leading to an intertrial interval of 3 s. Reversal of the stimulus-reward contingency occurs after 4--6 consecutive correct responses (i.e., if the car is rewarded and associated with a positive feedback, when a reversal occurs the car is suddenly no longer rewarded, but the spaceship is) (Fig. [1](#BHT365F1){ref-type="fig"}). The task ends after 20 reversal trials or after 20 min, whichever condition is met first. Zero to 2 probabilistic error trials (PETs), where a negative feedback is given for a correct response, are randomly interspersed between reversal trials to prevent subjects from predicting an upcoming reversal trial. PETs are at least 3 trials apart from other PETs and reversal trials. Brain activation to PETs are subtracted from brain activation to the final reversal error before a correct response. This stringent contrast captures the point at which subjects learn to reverse their response, and controls for the brain response to the punishment given in the negative feedback in both trials. This contrast has been used in previous fMRI studies of reward reversal learning ([@BHT365C25]; [@BHT365C103]). The main dependent variable is the number of perservative errors made after a reversal trial. Figure 1.Reward reversal learning task: subjects select an image (right/left) by pressing the corresponding button (right/left). If is the choice is correct/incorrect, positive/negative feedback is given. Once the subject has made 4--6 correct responses, the stimulus-reward contingency is reversed. PETs, where incorrect feedback is given for a correct response, are included to prevent subjects from predicting an upcoming reversal trial. The task contains on average 20 reversal trials with 20 interspersed PET trials.

Analysis of Performance Data {#s2c}
----------------------------

Two analyses of variance (ANOVAs) compared perseverative errors between controls and patients under either placebo or Fluoxetine. A repeated-measures ANOVA was conducted within the patient groups with group as an independent factor and drug as a repeated measure to test for group by medication interaction effects on performance. Bonferroni correction was used to correct for multiple comparisons.

fMRI Image Acquisition {#s2d}
----------------------

Gradient-echo echo-planar MR imaging (EPI) data were acquired on a General Electric Signa 3-T Horizon HDx system at the Centre For Neuroimaging Sciences, Institute of Psychiatry, UK. A semi-automated quality control procedure ensured consistent image quality ([@BHT365C125]). A quadrature birdcage headcoil was used for radio frequency transmission and reception. In each of 23 noncontiguous planes parallel to the anterior--posterior commissure, 800 *T*~2~\*-weighted MR images depicting blood oxygen level-dependent (BOLD) contrast covering the whole brain were acquired with time echo (TE) = 30 ms, time repetition (TR) = 1.5 s, flip angle = 70°, in-plane voxel size = 3 mm, slice thickness = 5.5 mm (including slice skip = 0.5 mm), and total acquisition time = 20 min. This EPI dataset provided almost complete brain coverage. A whole-brain high-resolution structural scan, (inversion recovery gradient-echo-planar image) on which to superimpose the individual activation maps, was also acquired in the intercommissural plane with TE = 30 ms, TR = 3 s, flip angle = 90°, 43 slices, slice thickness = 3.0 mm, slice skip = 0.3 mm, and in-plane voxel-size = 1.875 mm. The majority of the subjects conducted 3 more fMRI tasks in the same scanning session, which are not analyzed here. Total scanning time was 1 h.

fMRI Image Analysis {#s2e}
-------------------

The XBAM software package was used (<http://www.brainmap.co.uk>; [@BHT365C9]), which makes no normality assumptions (often violated in fMRI data), but instead uses median statistics to control outlier effects and permutation rather than normal theory-based inference. This method of fMRI analysis has been shown to be give excellent Type II error control, and there is evidence that permutation testing results in better sensitivity when compared with the more commonly used theory-based methods of analysis ([@BHT365C135]).

### Individual Analysis {#s2e1}

fMRI data were first processed to minimize motion-related artifacts ([@BHT365C12]). A 3-dimensional (3D) volume consisting of the average intensity at each voxel over the whole experiment was calculated and used as a template. The 3D image volume at each time point was then realigned to this template by computing the combination of rotations (around the *x*, *y*, and *z* axes) and translations (in *x*, *y*, and *z*) that maximized the correlation between the image intensities of the volume in question and the template (rigid-body registration). Following realignment, data were then smoothed using a Gaussian filter (full-width at half-maximum, 7.2 mm) to improve the signal-to-noise characteristics of the images. After motion correction, global detrending, and spin-excitation history correction, time series analysis for each subject was based on a wavelet-based data resampling method for fMRI data ([@BHT365C14]; [@BHT365C13]). At the individual-subject level, a standard general linear modeling approach was used to obtain estimates of the response size (beta) to each the reward reversal learning task conditions (final reversal error and probabilistic error) against an implicit baseline (repeat trials) and again for the higher level contrast of final reversal error trials minus PETs. Briefly, we first convolved the main experimental conditions (final reversal and PETs; each separately contrasted with repeat trials) and the higher level contrast (final reversal error trials minus PETs) with 2 Poisson model functions (peaking at 4 and 8 s). We then calculated the weighted sum of these 2 convolutions that gave the best fit (least squares) to the time series at each voxel. A goodness-of-fit statistic (the SSQ ratio) was then computed at each voxel consisting of the ratio of the sum of squares of deviations from the mean intensity value due to the model (fitted time series) divided by the that of squares due to the residuals (original time series minus model time series). The appropriate null distribution for assessing significance of any given SSQ ratio was established using a wavelet-based data re-sampling method ([@BHT365C13]) and applying the model-fitting process to the re-sampled data. This process was repeated 20 times at each voxel and the data combined over all voxels, resulting in 20 null parametric maps of SSQ ratio for each subject, which were combined to give the overall null distribution of SSQ ratio. The same permutation strategy was applied at each voxel to preserve spatial correlation structure in the data. Activated voxels, at a \<1 level of Type I error, were identified through the appropriate critical value of the SSQ ratio from the null distribution ([@BHT365C9]; [@BHT365C14]). Individual SSQ ratio maps were then transformed into standard space, first by rigid-body transformation of the fMRI data into a high-resolution inversion recovery image of the same subject, and then by affine transformation onto a Talairach template ([@BHT365C134]).

### Group Analysis {#s2e2}

A group activation map was produced for the experimental condition (final reversal error---probabilistic error) by calculating the median observed SSQ ratio over all subjects at each voxel in standard space and testing them against the null distribution of median SSQ ratios computed from the identically transformed wavelet re-sampled data ([@BHT365C9]; [@BHT365C13]). The voxel-level threshold was first set to 0.05 to give maximum sensitivity and to avoid Type II errors. Next, a cluster-level threshold was computed for the resulting 3D voxel clusters. The necessary combination of voxel and cluster-level thresholds was not assumed from theory, but rather was determined by direct permutation for each data set, giving excellent Type II error control ([@BHT365C14]). Cluster mass rather than a cluster extent threshold was used, to minimize discrimination against possible small, strongly responding foci of activation ([@BHT365C14]). In all group activation analyses, less than one false-positive activation locus was expected for *P* \< 0.05 at the voxel level and *P* \< 0.01 at the cluster level.

### ANCOVA Between-Group Difference Analyses {#s2e3}

For the between-group comparisons between controls and patients under either placebo or Fluoxetine, 1-way ANCOVAs with group as factor and rotational and translation movement in Euclidian 3D space as a covariate were conducted using randomization-based tests for voxel or cluster-wise differences as described in detail elsewhere ([@BHT365C14]; [@BHT365C13]). For these between-group comparisons, a *P*-value of *P* \< 0.05 was used for voxel and *P* \< 0.02 for cluster comparisons to achieve an optimal balance between Type II and Type I error. Then, the standardized BOLD response values (SSQ ratios) for each participant were extracted for each of the significant clusters of the 3-group ANCOVAs, and post hoc *t*-tests (correcting for multiple comparisons using least significant difference, LSD) were conducted to identify the direction of the between-group differences.

### ANCOVA Within-Patient Interaction Effects {#s2e4}

To investigate the group by drug interaction effects between placebo and Fluoxetine within the patient groups, a 2 × 2 ANCOVA (2 medication conditions and 2 groups) with rotational and translation movement in Euclidian 3D space as a covariate was conducted using randomization-based testing for voxel or cluster-wise differences as described elsewhere ([@BHT365C13]). Less than one false-positive 3D cluster was expected at *P* \< 0.05 at the voxel level and *P* \< 0.01 at the cluster level. Statistical measures of BOLD response for each participant were then extracted in each of the significant clusters, and post hoc *t*-tests (correcting for multiple comparisons with LSD) were conducted to identify the direction of the interaction effects.

### Normalization Effects {#s2e5}

To test for the statistical significance of any apparent normalization effects of Fluoxetine on case-control activation differences observed under placebo, we used repeated-measures *t*-tests on the extracted BOLD responses during each medication condition for each of the clusters shown to be significantly different in the comparison between controls and patients during placebo. We conducted this test only within patients, given that controls were only tested once, and hence constant across comparisons.

Results {#s3}
=======

Participant Characteristics {#s3a}
---------------------------

ANOVAs showed no significant group differences in age \[median age: controls: 13.7 (SD = 2.6); ADHD: 15.2 (SD = 1.8); ASD: 15.1 (SD = 1.9)\], but did in IQ (*F*~df=2,53~ = 7, *P* \< 0.002), which was significantly lower in ADHD relative to control and ASD boys (*P* \< 0.005), who did not differ from each other. ADHD children typically have lower IQ than their healthy peers ([@BHT365C10]). Therefore, IQ was not covaried, as when the covariate is intrinsic to the condition, and differs between groups who were not randomly selected, it violates ANCOVA assumptions ([@BHT365C35]). Nonetheless, to assess the potential impact of IQ on group differences and group by medication interaction effects, the analyses were repeated with IQ as a covariate.

Performance Data {#s3b}
----------------

ANOVA between controls and patients under placebo showed no significant group effect (*F*~df=2,53~ = 2, *P* = 0.170), although both patient groups made numerically more errors than controls with a relatively large effect size of 0.67 for ADHD and a medium effect size of 0.48 for ASD. When patients were under Fluoxetine, there was a significant group effect for perseverative errors (*F*~df=2,53~ = 4, *P* \< 0.05) that were significantly higher in ADHD under Fluoxetine relative to controls (*P* \< 0.005), which survived Bonferroni correction for multiple comparisons (*P* \< 0.05) \[mean perseverative errors: controls: 1.4 (SD = 0.3); ADHD placebo: 1.7 (SD = 0.5); ADHD Fluoxetine: 1.8 (SD = 0.4); ASD placebo: 1.7 (SD = 0.6); ASD Fluoxetine: 1.6 (0.4)\]. However, for the within-patient analyses, no interaction effects were observed between groups (ADHD; ASD) and medication status (placebo; fluoxetine), suggesting that fluoxetine had no differential effect on performance in either group.

fMRI Data {#s3c}
---------

### Movement {#s3c1}

Repeated-measures ANOVAs using group as an independent factor and maximum *x*, *y*, and *z* rotation or maximum *x*, *y*, and *z* translation as repeated measures showed that there were no significant group by movement interaction effects in rotation (*F*~df=4,102~ = 2, *P* = n.s.) or translation (*F*~df=4,102~ = 2, *P* = n.s). Nevertheless, to eliminate any potential effects of nonsignificant variance in motion, 3D Euclidean motion parameters were used as covariates in fMRI analysis.

Group Brain Activation Maps {#s3d}
---------------------------

### Final Reversal Error---Probabilistic Error {#s3d1}

#### Controls {#s3d1a}

Controls activated a bilateral network consisting of mPFC, supplementary motor area (SMA), ACC, precentral/postcentral gyri, inferior/middle/superior frontal cortices, basal ganglia, thalamus, midbrain, and posterior cingulate cortex (PCC)/precuneus (Fig. [2](#BHT365F2){ref-type="fig"}*A*) Figure 2.Within-group activation for (*A*) Healthy controls, (*B*) adolescents with ADHD under either placebo or Fluoxetine, and (*C*) adolescents with ASD under either placebo or Fluoxetine for the contrast of final reversal error--probabilistic error. Axial sections showing within-group brain activation for healthy control boys, boys with ADHD under either placebo or Fluoxetine, and boys with ASD under either placebo or Fluoxetine for the contrast of final reversal error -- probabilistic error. Talairach *z* co-ordinates are indicated for slice distance (in mm) from the intercommissural line. The right side corresponds to the right side of the image.

#### Attention Deficit Hyperactivity Disorder {#s3d1b}

Under placebo, ADHD subjects activated mPFC/ACC, left precentral/postcentral gyri, right middle frontal cortex, bilateral IFC/insula, putamen, and left inferior- and right superior-parietal lobes. Under Fluoxetine, ADHD subjects activated SMA, left superior parietal lobe, and right hippocampal gyrus (Fig. [2](#BHT365F2){ref-type="fig"}*B*).

#### Autism Spectrum Disorder {#s3d1c}

Under placebo, ASD subjects activated bilateral IFC/caudate/putamen and a right hemispheric network consisting of precentral/postcentral gyrus, inferior/superior parietal lobe, precuneus, and fusiform gyrus/cerebellum. Under Fluoxetine, ASD subjects activated a right hemispheric network consisting of middle/superior frontal cortex, superior parietal lobe, and precuneus (Fig. [2](#BHT365F2){ref-type="fig"}*C*).

Between-Group Differences Between Controls and Patients Under Placebo {#s3e}
---------------------------------------------------------------------

ANCOVA between controls and patients under placebo showed significant group effects in mPFC \[23 voxels, peak Talairach co-ordinates (*x*, *y*, *z*): −4, 52, 20; BA 10/9\] and precuneus reaching into PCC \[11 voxels, peak Talairach co-ordinates (*x*, *y*, *z*): 0, −52, 26; BA 31/7) (Fig. [3](#BHT365F3){ref-type="fig"}*A*). Post hoc analyses showed that the group effect in mPFC was due to significantly decreased activation in ASD compared with controls (*P* \< 0.0001) and ADHD (*P* \< 0.0001), who did not differ from each other. In precuneus, both the ADHD (*P* \< 0.005) and ASD (*P* \< 0.05) groups, who did not differ from each other, had significantly decreased activation compared with controls. Figure 3.(*A*) Between-group and within-patient comparisons: axial sections showing the between-group ANCOVA findings between controls and patients under placebo. Shown underneath are the statistical measures of BOLD response for each of the 3 groups for each of the brain regions that showed a significant group effect. mPFC, medial prefrontal cortex. Error bars indicate standard error. (*B*) Axial sections for the between-group ANCOVA comparison between controls and patients under Fluoxetine. (*C*) Axial sections showing within-patient group by medication interaction effects. Talairach *z* co-ordinates are indicated for slice distance (in mm) from the intercommissural line. The right side of the image corresponds to the right side of the brain.

To test whether group effects were related to performance or behavior, we correlated the statistical BOLD response in the group difference clusters with perseverative errors and behavioral scores within each group. The activation in precuneus in ASD was positively correlated with perservative errors (*r* = 0.5, *P* \< 0.05). No other correlations were significant.

Between-Group Differences Between Controls and Patients Under Fluoxetine {#s3f}
------------------------------------------------------------------------

ANCOVA between controls and patients under Fluoxetine showed a significant group effect in left insula reaching into putamen \[23 voxels, peak Talairach co-ordinates (*x*, *y*, *z*): −33, 19, 4; BA 13) (Fig. [3](#BHT365F3){ref-type="fig"}*B*). Post hoc analyses showed that this difference was due to significantly reduced activation in the ASD group compared with controls (*P* \< 0.005), who did not differ from ADHD.

Repeated-measures *t*-tests showed a significant effect of drug condition in mPFC (*P* = 0.003), which was due to significantly increased activation in mPFC in the ASD group under Fluoxetine relative to placebo. A significant drug effect was also observed in precuneus (*P* \< 0.05), which was due to significantly increased activation in this region in the ADHD group under Fluoxetine relative to placebo. No other significant normalization effects were observed.

Correlation analyses showed that the (reduced) activation in left insula in ASD was negatively correlated with scores on the social domain of the ADI (*r* = −0.5, *P* \< 0.05). No other correlations were significant.

To assess the potential impact of IQ on case-control group differences, all analyses were repeated with IQ as a covariate. All clusters remained at *P* \< 0.05 for placebo and at *P* \< 0.02 for Fluoxetine.

Within-Patient Group by Medication Interaction Effects {#s3g}
------------------------------------------------------

Repeated-measures ANCOVA showed a significant group by medication interaction effect in mPFC \[41 voxels, peak Talairach co-ordinates (*x*, *y*, *z*): 0, 63, 15; BA 10/9), due to Fluoxetine increasing activation in this area in the ASD group and decreasing it in the ADHD group (Fig. [3](#BHT365F3){ref-type="fig"}*C*). This remained significant when IQ was covaried for.

Discussion {#s4}
==========

This study shows that, during the final stage of reward reversal, contrasted with probabilistic errors, ASD boys have disorder-specific underactivation in mPFC, a key region of reward-related decision-making, relative to ADHD and control boys, and also shared underactivation with ADHD boys, relative to controls, in precuneus, a key region of error processing. Fluoxetine had an inverse, disorder-specific effect in mPFC as it increased activation in ASD boys, leading to normalization of their dysfunction relative to controls, but decreased activation in ADHD boys, concomitant with deteriorated task performance relative to controls. The findings suggest that Fluoxetine has disorder-dissociative, inverse modulation effects on a key region of reward reversal, potentially reflecting differential baseline 5-HT levels in both disorders.

ASD boys compared with the other 2 groups showed disorder-specific underactivation in a key region of reward reversal ([@BHT365C103]; [@BHT365C47]; [@BHT365C80]) and reward-related decision-making ([@BHT365C43]) that is particularly sensitive to negative feedback, mediating shifting away from disadvantageous responses after negative feedback ([@BHT365C18]; [@BHT365C52]). Dysfunction in mPFC in ASD may be related to evidence for abnormally increased gray matter in the mPFC in adolescent boys with ASD compared with controls ([@BHT365C7]), indicative of poor synaptic pruning and of poor 5-HT binding in mPFC in ASD adolescents ([@BHT365C77]). Although ASD patients were not significantly impaired in the task, they had numerically more perseverative errors with a medium effect size (0.48), which may have reached significance in a larger cohort. The disorder specificity of the brain dysfunction to ASD was unexpected. However, the only previous fMRI study that used a similar reward reversal task and contrast found enhanced mPFC activation in ADHD relative to controls ([@BHT365C47]). Taken together, the findings of these 2 studies suggest that medial underactivation may not be a neurofunctional feature of ADHD in the context of reward reversal, while lateral prefrontal underactivation in ADHD patients relative to controls is well documented during other cognitive control tasks that are mediated by lateral prefrontal regions ([@BHT365C115], [@BHT365C116]; [@BHT365C130]; [@BHT365C110]; [@BHT365C111]; [@BHT365C108]; [@BHT365C60]).

It is interesting that, during placebo, only individuals with ASD had reduced mPFC activation while ADHD patients did not differ from controls. There is consistent evidence that ADHD patients have abnormal activation in more lateral prefrontal-striato-parietal circuitries, most prominently in inferior prefrontal cortex and caudate during tasks of cognitive control, attention, switching, and timing ([@BHT365C113], [@BHT365C115], [@BHT365C112]; [@BHT365C130], [@BHT365C129]; [@BHT365C110]; [@BHT365C59], [@BHT365C60]). Therefore, the evidence for functional deficits in ADHD points toward abnormalities in lateral cognitive fronto-striato-parietal networks with relatively little evidence for abnormalities in mPFC-limbic regions during cognitive flexibility or reward-related tasks. In fact, the only prior study of reward reversal learning found increased mPFC activation in ADHD patients during reversal errors ([@BHT365C47]). The deficits in lateral cognitive fronto-striato-parietal circuitries may be related to evidence for delayed maturation of cortical thickness in these fronto-parieto-temporal regions ([@BHT365C152], [@BHT365C153]). Adolescents and adults with ASD, on the other hand, have more commonly been shown to have reduced activation in mPFC and their associated limbic-temporal regions during tasks of reward, emotion processing, and cognitive control ([@BHT365C122]; [@BHT365C38]; [@BHT365C136]; [@BHT365C96]), which may be related to abnormal maturation patterns in ASD patients in these regions ([@BHT365C17]; [@BHT365C100]; [@BHT365C133]). Children with ASD, unlike ADHD children, who show delayed maturation of fronto-cortical regions ([@BHT365C152], [@BHT365C153]), undergo a period of abnormal brain overgrowth in young childhood followed by a period of decreased growth, compared with controls ([@BHT365C28], [@BHT365C27]; [@BHT365C1]; [@BHT365C133]). Hence, rather than a delay of brain maturation like in ADHD, there is evidence for a deviance from normal brain maturation in ASD with early overgrowth followed by abnormal growth patterns later on in adolescence and adulthood. Furthermore, in ASD individuals, there is increasing evidence for abnormal white matter integrity between fronto-limbic and fronto-striatal brain regions, compared with controls ([@BHT365C100]; [@BHT365C72]; [@BHT365C94]; [@BHT365C98]). This is of particular interest as it has been shown that the ventromedial fronto-basal ganglia-thalamo-cortical loops are involved in habit formation, reward processing, and stimulus-response associations ([@BHT365C93]; [@BHT365C147]; [@BHT365C58]). Although poor fronto-striatal and fronto-parietal white matter tract connectivities have also consistently been reported in children with ADHD, fronto-limbic structural connectivity abnormalities have not been frequently associated with ADHD ([@BHT365C70]; [@BHT365C138]). Given that the mPFC is part of a fronto-striato-limbic reward processing network, this may account for the disorder-specific reduced mPFC activation in the ASD group.

The shared dysfunction in precuneus is interesting as this region is closely interconnected with the mPFC ([@BHT365C128]) and plays a key role in reversal learning ([@BHT365C41]; [@BHT365C52]), reward evaluation ([@BHT365C78]; [@BHT365C73]), and visual--spatial attention to saliency, in particular error processing ([@BHT365C114], [@BHT365C117]; [@BHT365C128]; [@BHT365C104]; [@BHT365C71]). Findings of precuneus dysfunction in ADHD during reward reversal learning extend prior evidence for precuneus dysfunction in response to salient events such as errors and rewarded trials in other tasks ([@BHT365C115], [@BHT365C116]; [@BHT365C108]), presumably reflecting poor saliency and error processing. In ASD, the precuneus has been found to be underactivated during interference ([@BHT365C131]) and motor inhibition ([@BHT365C68]). The behavioral significance of the abnormal precuneus activation in the ASD group is shown by the positive correlation of this activation with perservative errors. It has been shown that errors elicit the activation of an error detection network that comprises anterior and posterior cingulate as well as precuneus ([@BHT365C128]; [@BHT365C104]; [@BHT365C117]; [@BHT365C71]). ASD patients committed more peseverative errors with a medium effect size than controls, and the enhanced number of errors may be caused by the diminished precuneus activation, given that higher precuneus activation reflects better error monitoring in ASD patients.

The most intriguing finding is the inverse effect of Fluoxetine on mPFC activation in the 2 disorders, upregulating and normalizing it in ASD, but decreasing it in ADHD. This inverse effect could potentially reflect disorder differences in baseline levels of 5-HT. Approximately 30% of individuals with ASD have enhanced platelet 5-HT levels (i.e., hyperserotonemia) ([@BHT365C97]; [@BHT365C82]; [@BHT365C65]). There is evidence for reduced binding to 5-HT transporters in the mPFC of individuals with ASD ([@BHT365C77]; [@BHT365C86]) as well as reduced 5-HT~2A~ receptor binding ([@BHT365C84]) and altered 5-HT synthesis ([@BHT365C22], [@BHT365C21]). This suggests that hyperserotonemia may be an adaptation to counteract poor 5-HT receptor binding and abnormal 5-HT synthesis. An increase in 5-HT with Fluoxetine may have increased ligand-receptor binding sufficiently to enhance activation in areas, where 5-HT receptor density is typically low. In addition, Fluoxetine may have amended an abnormal "balance" of 5-HT, therefore improving the homeostatic role of this key neurotransmitter and potentially leading to an increase in mPFC activation in ASD ([@BHT365C40]; [@BHT365C83]). Furthermore, each brain region has a distinct serotonergic profile, with limbic and more medial structures receiving dense serotonergic innervation ([@BHT365C67]; [@BHT365C139]). This therefore makes regions such as the mPFC highly susceptible to serotonergic manipulation, particularly in a patient group which have shown structural ([@BHT365C7]) and biochemical ([@BHT365C84]; [@BHT365C77]; [@BHT365C86]) abnormalities in this region. It is also plausible that an increase in 5-HT may be modulating primary 5-HT abnormalities in transporter function ([@BHT365C77]; [@BHT365C86]) or 5-HT~2A~ receptor binding ([@BHT365C84]), which have been reported to be impaired in the mPFC of ASD individuals ([@BHT365C84]; [@BHT365C77]; [@BHT365C86]), and may have led to the increased activation in mPFC observed in the ASD group. Our finding of an upregulation and normalization of Fluoxetine in the mPFC of adolescents with ASD extends prior evidence that SSRIs increase metabolic and neurofunctional activities in prefrontal areas in adults with ASD ([@BHT365C11]; [@BHT365C37]).

Fluoxetine also decreased insula activation in ASD relative to controls. There is consistent evidence for underactivation and underconnectivity of the insula in individuals with ASD ([@BHT365C136]; [@BHT365C42]). However, this was mainly observed during tasks of emotion processing and there is evidence that this underactivation is associated with alexithymia in ASD, as opposed to social interaction deficits ([@BHT365C6]). The insula forms part of a mPFC-striato-limbic network for reward-related decision-making and, like mPFC, is particularly sensitive to negative feedback and mediates shifting away from disadvantageous choices in both gambling ([@BHT365C18]; [@BHT365C19]) and reward reversal learning tasks ([@BHT365C90]; [@BHT365C103]; [@BHT365C23]). The normalization of mPFC activation with Fluoxetine may have resulted in the impairment of a limbic part of the reversal network, suggesting that brain function was not entirely normalized. Alternatively, insula activation has been observed in uncertain conditions during probabilistic tasks ([@BHT365C66]) and is associated with anxiety to the anticipation of aversive stimuli ([@BHT365C95]; [@BHT365C126])**,** both of which are key aspects of reward reversal learning. Therefore, the decreased activation in this area in ASD boys may have been a reflection of a reduction in their anxiety to the negative feedback they received when they reversed their response. This is in line with the behavioral correlations which found that the higher the social impairment on the ADI subscale, and therefore the more anxious the individual is likely to be, the more Fluoxetine decreased insula activation.

The reduction of activation in mPFC in ADHD with Fluoxetine was unexpected. However, ADHD boys, unlike ASD boys, showed no underactivation in this region, and hence, the 5-HT modulation may have interfered with normal prefrontal activation. This is further supported by the finding of performance impairment with 5-HT in ADHD. While ADHD patients have shown lateral prefronto-striatal underactivation during switching tasks ([@BHT365C130]; [@BHT365C110]; [@BHT365C111]), the only previous fMRI study on a similar contrast in a reward reversal task found increased mPFC activation in ADHD relative to controls ([@BHT365C47]). Hence, reward reversal tasks may not elicit underactivation in key areas of reversal processes and therefore not tap into the dysfunctional brain mechanisms of ADHD. Furthermore, although there is evidence of serotonergic dysfunction in ADHD at both a genetic ([@BHT365C53]) and biochemical ([@BHT365C132]) level, potentially leading to low 5-HT, the positive clinical effect of Fluoxetine monotherapy ([@BHT365C5]; [@BHT365C99]) and the modulating effect of Fluoxetine on Methylphenidate therapy ([@BHT365C51]; [@BHT365C46]) may be due to the interaction between the increase in 5-HT, a key regulatory neurotransmitter, and dopamine, a neurotransmitter which is known to be low in individuals with ADHD ([@BHT365C140]; [@BHT365C32]). Studies in rats have found that increased impulsivity is associated with 5-HT levels in the mPFC, highlighting the importance of 5-HT in this area in disorders of inhibition and impulsivity, and it is known that both 5-HT and dopamine are involved in inhibition ([@BHT365C31], [@BHT365C29]). Antagonism of the 5-HT~2C~ receptor, leading to less 5-HT-mediated inhibition of dopamine release, leads to better reversal learning in rats and shows that the interplay between 5-HT and dopamine, as well as absolute 5-HT levels, is involved in reversal learning ([@BHT365C8]). Interestingly, a decrease in 5-HT with acute tryptophan depletion has been shown to lead to increased activation in the mPFC of healthy individuals during a task of reward reversal learning ([@BHT365C44]). Therefore, it appears as if 5-HT agonists may perturb the delicate serotonin-dopamine balance in mPFC, an area which is normal in ADHD in this task context, leading to decreased activation. Given that 11 ADHD patients were withdrawn from medication for 48 h, it cannot be excluded that the withdrawal effect or the interaction of the dopamine withdrawal effect combined with the acute SSRI effect may have affected brain activation or performance ([@BHT365C151]).It is also possible that the long-term effect of stimulant medication on brain structure and function ([@BHT365C87]; [@BHT365C59], [@BHT365C60]; [@BHT365C109]) in the 11 medicated ADHD participants may have influenced the findings. However, both withdrawal and long-term stimulant effects would have been contrasted out by the placebo control condition.

In ASD, however, 5-HT is thought to be the main abnormal neurotransmitter in the disorder, and there is a wealth of research supporting the presence of genetic and biochemical serotonergic abnormalities, leading to high levels of 5-HT ([@BHT365C97]; [@BHT365C22], [@BHT365C21]; [@BHT365C82]; [@BHT365C84]; [@BHT365C65]; [@BHT365C77]; [@BHT365C148]; [@BHT365C86]), in addition to the positive effect of Fluoxetine on stereotyped behaviors ([@BHT365C45]; [@BHT365C63], [@BHT365C64]; [@BHT365C15]) and brain activation in areas related to reward reversal ([@BHT365C11]; [@BHT365C37]) in children and adults with ASD. These differing biochemical abnormalities may have accounted for the positive upregulation effect of Fluoxetine on ASD mPFC activation and its negative downregulating effect on mPFC activation in ADHD.

Despite significant effects on brain activation in both ADHD and ASD boys, Fluoxetine only had a behavioral effect in the ADHD group when compared with controls, leading patients to perform worse than controls under Fluoxetine, but not placebo. It has previously been shown in similar reward reversal learning tasks that brain function is more sensitive to pharmacological manipulations than performance ([@BHT365C44]). In addition, although a sample size of 15--18 is adequate for fMRI analysis ([@BHT365C135]), it is likely to be insufficient to detect more subtle neuropsychological differences, such as those that may be present between the ASD and control group.

The strengths of this study are the carefully selected, noncomorbid patient groups and the medication-naivety of the ASD group. Although there is a significant clinical overlap between ADHD and ASD ([@BHT365C137]; [@BHT365C101]), rigorous screening ensured that no overlap was present between the 2 patient groups in this study. Although at the time of study DSM-V was not available, and might have enabled easier identification and exclusion of comorbid cases, we are confident that our rigorous screening ensured that none of the patients had comorbidity with the other disorder. This is of great importance as there is an increasing need to find objective, biological biomarkers with the potential to aid in the differential diagnosis of these 2 neurodevelopmental disorders. While testing clearly noncomorbid patient groups is an advantage for studies such as our own which aim to elucidate the differences and commonalities in neural substrates and drug manipulations between the 2 disorders, a limitation is that the data cannot be generalized to the commonly occurring overlapping disorder type. Future studies should compare pure disorder groups as well as comorbid conditions in order to disentangle the underlying neural substrates of these and the effect of serotonin manipulations.

A limitation is the lower IQ in the ADHD group. However, covariance analysis showed that this did not affect the main findings. The use of an acute dose of Fluoxetine may be considered another limitation. However, studies on acute dose effects have the advantage to allow to investigate brain activation effects of medication without the confound of side effects and long-term chronic effects on behavior and cognition, and are often a necessary first step for proof of concept. However, they are limited in that they cannot investigate the association between brain activation effects and clinical improvement over a longer period of time such as several weeks, which is when Fluoxetine typically starts to show clinical efficacy. This is an area which should be focused on in future research, particularly as protracted courses of Fluoxetine are used in the clinical trials that report an improvement in behavior in ADHD ([@BHT365C5]; [@BHT365C51]; [@BHT365C99]) and ASD children ([@BHT365C34], [@BHT365C33]; [@BHT365C63]). In addition, the mechanisms of action of these long-term effects need also be understood. Another limitation is that both patient groups were scanned twice, while controls were only scanned once. While training effects are counter-balanced between medication conditions, it cannot be ruled out that the fact that patients conducted the task twice might have affected the performance or brain activation findings.

To summarize, we found disorder-specific underactivation in ASD boys in mPFC, a key region of reversal learning, as well as disorder-dissociated inverse effects of Fluoxetine on this region, which upregulated and normalized dysfunction in ASD but down-regulated activation in ADHD, concomitant with worsening their task performance. The findings may indicate dissociated underlying 5-HT abnormalities in the 2 disorders.
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